Authors
Mitchell G Miglis, Charles H Adler, Elena Antelmi, Dario Arnaldi, Luca Baldelli, Bradley F Boeve, Matteo Cesari, Irene Dall'Antonia, Nico J Diederich, Kathrin Doppler, Petr Dušek, Raffaele Ferri, Jean-François Gagnon, Ziv Gan-Or, Wiebke Hermann, Birgit Högl, Michele T Hu, Alex Iranzo, Annette Janzen, Anastasia Kuzkina, Jee-Young Lee, Klaus L Leenders, Simon JG Lewis, Claudio Liguori, Jun Liu, Christine Lo, Kaylena A Ehgoetz Martens, Jiri Nepozitek, Giuseppe Plazzi, Federica Provini, Monica Puligheddu, Michal Rolinski, Jan Rusz, Ambra Stefani, Rebekah LS Summers, Dallah Yoo, Jennifer Zitser, Wolfgang H Oertel
Publication date
2021/8/1
Source
The Lancet Neurology
Volume
20
Issue
8
Pages
671-684
Publisher
Elsevier
Description
Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α …
Total citations
Scholar articles
MG Miglis, CH Adler, E Antelmi, D Arnaldi, L Baldelli… - The Lancet Neurology, 2021